Clinical trials, drug development and research news
Patient GuidesSome treatments cannot be disguised. This guide explains open-label trials, the biases they risk and how to judge them, using the LATE-MT stroke and SINGLE-AF trials.
30 October 2026
Drug ApprovalsThe MHRA has extended Casgevy to children from age five with severe sickle cell disease or thalassaemia, and NICE has widened NHS managed access to match.
30 October 2026
Voceryq won accelerated approval after a trial of 32 adults in which about a quarter needed no surgery for their papillomas in the following year. The FDA granted accelerated approval to Voceryq on 30 October 2026 for adults with recurrent respiratory papillomatosis (RRP), a rare disease in which HPV causes wart-like growths in the airway.
· 30 October 2026
The Briefing
One email. The week's readouts, approvals and research, explained without hype.
OncologyAdding tarlatamab to durvalumab maintenance raised median survival from 12.7 to 21.1 months in extensive-stage small cell lung cancer, with mostly mild immune reactions.
24 October 2026
OncologyIn the VOLGA trial, durvalumab plus enfortumab vedotin around bladder removal lifted two-year survival from 69% to 78% for people who couldn't or wouldn't have cisplatin.
24 October 2026
OncologyA vaccine built from each patient's own tumour, given with pembrolizumab, kept 82% of people relapse-free at two years against 70% on pembrolizumab alone.
24 October 2026
OncologyFinal CheckMate 8HW data show nivolumab plus ipilimumab left 77% of people with MSI-high metastatic bowel cancer alive at five years, against 46% on chemotherapy.
24 October 2026
OncologyFinal BEATcc results show adding atezolizumab to chemotherapy and bevacizumab extended median survival by 9.2 months in advanced cervical cancer, after almost five years of follow-up.
24 October 2026
Rare DiseasesIn the Lancet-published RISE UP trial, mitapivat raised haemoglobin in 41% of people with sickle cell disease against 3% on placebo, but pain crises didn't fall significantly.
22 October 2026
Rare DiseasesIn the ORIGIN 3 trial, people with IgA nephropathy on weekly atacicept lost almost no kidney function over two years, against about 5.6 eGFR units a year on placebo.
22 October 2026
Rare DiseasesPhase 3 APOLLO results show bitopertin added about 12 pain-free hours in light each month and cut painful reactions by 71% in erythropoietic protoporphyria, a rare inherited condition.
19 October 2026
Rare DiseasesFour-year data on uniQure's AMT-130 show slower loss of daily function at the high dose, though the main rating scale result was no longer statistically significant.
29 September 2026
Rare DiseasesIonis and Otsuka say ulefnersen improved survival and function in the phase 3 FUSION trial in FUS-ALS, an aggressive genetic motor neurone disease often seen in teenagers.
22 September 2026
CardiologyIn PADN-HF-PH, adding pulmonary artery denervation to standard medicines halved clinical worsening in heart failure patients with raised lung pressure over about a year.
30 August 2026
CardiologyIn the TRIC-I-HF trial, repairing the tricuspid valve through a vein raised the share alive and out of hospital at three years from 21% to 52%.
30 August 2026
CardiologyIn the AIR-STEMI trial, software that measures blood flow from routine angiograms meant fewer stents, fewer complications and fewer repeat heart events than judging by eye.
29 August 2026
CardiologyIn LIBREXIA ACS, milvexian did not reduce heart attacks, strokes or heart deaths after acute coronary syndrome, though it also didn't increase serious bleeding.
29 August 2026
CardiologyAficamten met both main goals in the ACACIA-HCM trial, modestly improving symptoms and exercise capacity in nonobstructive hypertrophic cardiomyopathy, a condition with no targeted treatment.
28 August 2026
NeurologyIn the REMODEL trials of 2,007 people, remibrutinib cut relapses by about a third and new brain lesions by two thirds against teriflunomide, without liver problems.
23 October 2026
NeurologyThe long-delayed Cognite trial of 619 people found inhaled cromolyn plus low-dose ibuprofen did no better than either drug alone, with a non-significant signal in APOE4 non-carriers.
23 October 2026
NeurologyIn the LATE-MT trial, thrombectomy 24 to 72 hours after a major stroke helped more people regain independence, but raised brain bleeding and deaths.
23 October 2026
NeurologyIn the NOPARK trial of 410 people with early Parkinson's, a year of nicotinamide riboside left symptoms slightly worse than placebo, despite raising NAD levels in the blood.
8 October 2026
NeurologyIn the phase 3 ARISE trial, once-daily solengepras cut daily OFF time by 0.61 hours against placebo and improved daily function, alertness and quality of life.
6 October 2026
Drug ApprovalsVoceryq won accelerated approval after a trial of 32 adults in which about a quarter needed no surgery for their papillomas in the following year.
30 October 2026
Drug ApprovalsThe MHRA has extended Casgevy to children from age five with severe sickle cell disease or thalassaemia, and NICE has widened NHS managed access to match.
30 October 2026
Drug ApprovalsThe FDA has cleared talazoparib with enzalutamide for gene-mutated hormone-sensitive prostate cancer after TALAPRO-3 cut the risk of scan progression or death by 52%.
26 October 2026
Drug ApprovalsThe MHRA has approved Icotyde for moderate to severe plaque psoriasis from age 12, after trials in which it beat placebo and an existing oral psoriasis pill.
23 October 2026
Drug ApprovalsHibsago, an antisense injection from GSK, gave about one in five eligible adults a functional cure in two phase 3 trials, against none on placebo.
20 October 2026
Patient GuidesSome treatments cannot be disguised. This guide explains open-label trials, the biases they risk and how to judge them, using the LATE-MT stroke and SINGLE-AF trials.
30 October 2026
Patient GuidesWorried about getting a dummy pill in a trial? This guide explains placebos, blinding and your rights, using Norway's NOPARK Parkinson's trial as a worked example.
27 October 2026
Patient GuidesA missed primary endpoint is still evidence. Using the 2026 CARDIO-TTRansform trial, this guide explains neutral results, subgroups, safety and what happens next for patients.
23 October 2026
Patient GuidesA 69% risk cut can mean a handful of people. This guide shows how to read absolute risk, NNT, confidence intervals and p-values using a real 2026 trial.
20 October 2026
Patient GuidesWhere to search, how to read a trial listing, what to ask before you sign and your rights once you join, for patients in the UK, US and EU.
9 October 2026
Industry & RegulationSix months into the UK's new clinical trial regulations, the MHRA reports seven-day average approvals for low-risk changes and lists the mistakes that still delay applications.
28 October 2026
Industry & RegulationThe UK regulator's five-year plan sets guaranteed assessment times backed by fee rebates, an AI protocol checker and a goal of third place globally for phase 1 trials.
14 October 2026
Industry & RegulationThe EMA says the proposed Biotech Act affects about 70% of the EU clinical trials system, with first changes possible in 2028 as the FAST-EU pilot tests 70-day approvals.
1 October 2026
Industry & RegulationThe Council has adopted the biggest rewrite of EU medicines law in two decades, changing protection periods, orphan exclusivity, antibiotic incentives and EMA review times.
28 September 2026
Industry & RegulationDrug sponsors can now pair with qualified research institutions for rolling FDA review of investigational new drug applications, as the agency tries to shorten first-in-human timelines.
15 September 2026